These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 31807015)
1. Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer. Radosevich JA; Babich M Onco Targets Ther; 2019; 12():9351-9354. PubMed ID: 31807015 [TBL] [Abstract][Full Text] [Related]
2. Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen. Babich M; Sharma A; Li T; Radosevich JA Heliyon; 2022 Mar; 8(3):e08988. PubMed ID: 35252607 [TBL] [Abstract][Full Text] [Related]
3. Topology and adenocarcinoma cell localization dataset on the labyrinthin diapeutic biomarker. Sharma A; Babich M; Li T; Radosevich JA BMC Res Notes; 2023 Jul; 16(1):139. PubMed ID: 37415228 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 44-3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids. Cajulis RS; Szumel R; Frias-Hidvegi D; Combs SG; Radosevich JA Diagn Cytopathol; 1993; 9(2):179-83. PubMed ID: 8513714 [TBL] [Abstract][Full Text] [Related]
5. Expression of the antigenic determinant recognized by the monoclonal antibody 44-3A6 on select human adenocarcinomas and normal human tissues. Combs SG; Radosevich JA; Ma Y; Lee I; Gould VE; Battifora H; Rosen ST Tumour Biol; 1988; 9(2-3):116-22. PubMed ID: 2456598 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody 44-3A6 as a marker for breast carcinoma. Duda RB; August CZ; Rosen ST; Radosevich JA Tumour Biol; 1991; 12(5):254-60. PubMed ID: 1660186 [TBL] [Abstract][Full Text] [Related]
7. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
8. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Ordóñez NG Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183 [TBL] [Abstract][Full Text] [Related]
9. Expression of the adenocarcinoma-related antigen recognized by monoclonal antibody 44-3A6 in salivary gland neoplasias. Bentz BG; Haines GK; vonSchlegell AS; Elseth KM; Hanson DG; Radosevich JA Otolaryngol Head Neck Surg; 1998 May; 118(5):603-9. PubMed ID: 9591857 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of human pulmonary carcinomas using monoclonal antibody 44-3A6. Lee I; Radosevich JA; Ma YX; Combs SG; Rosen ST; Gould VE Cancer Res; 1985 Nov; 45(11 Pt 2):5813-7. PubMed ID: 2414000 [TBL] [Abstract][Full Text] [Related]
11. Application of monoclonal antibody 44-3A6 in the cytodiagnosis and classification of pulmonary carcinomas. Banner BF; Gould VE; Radosevich JA; Ma Y; Lee I; Rosen ST Diagn Cytopathol; 1985; 1(4):300-7. PubMed ID: 3836094 [TBL] [Abstract][Full Text] [Related]
12. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Spagnolo DV; Whitaker D; Carrello S; Radosevich JA; Rosen ST; Gould VE Am J Clin Pathol; 1991 Mar; 95(3):322-9. PubMed ID: 1705090 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of human adenocarcinomas of the lung using the monoclonal antibody 44-3A6. Radosevich JA; Noguchi M; Rosen ST; Shimosato Y Tumour Biol; 1990; 11(4):181-8. PubMed ID: 2371495 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody 44-3A6 as a probe for a novel antigen found on human lung carcinomas with glandular differentiation. Radosevich JA; Ma YX; Lee I; Salwen HR; Gould VE; Rosen ST Cancer Res; 1985 Nov; 45(11 Pt 2):5808-12. PubMed ID: 2413999 [TBL] [Abstract][Full Text] [Related]
15. Serum carbohydrate antigen elevations in endometrial adenocarcinomas: characterization of DU-PAN-2 expression as a tumor marker. Yasuda M; Saito K; Kobayashi Y; Muramatsu T; Miyamoto T; Murakami M; Shinozuka T; Ishizuka B; Makino T; Kajiwara H; Osamura RY J Obstet Gynaecol Res; 2004 Feb; 30(1):59-64. PubMed ID: 14718023 [TBL] [Abstract][Full Text] [Related]
16. Expression of the epitope recognized by the monoclonal antibody 44-3A6 during human fetal development. Radosevich JA; Combs SG; Rosen ST Tumour Biol; 1991; 12(6):321-9. PubMed ID: 1724706 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Sinkule JA; Rosen ST; Radosevich JA Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554 [TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography. Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961 [TBL] [Abstract][Full Text] [Related]
19. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Haisma HJ; Pinedo HM; Rijswijk A; der Meulen-Muileman I; Sosnowski BA; Ying W; Beusechem VW; Tillman BW; Gerritsen WR; Curiel DT Gene Ther; 1999 Aug; 6(8):1469-74. PubMed ID: 10467371 [TBL] [Abstract][Full Text] [Related]
20. A new tumor marker MCA in breast cancer diagnosis. Eskelinen M; Tikanoja S; Collan Y Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]